FEMASYS INC (FEMY): Price and Financial Metrics
GET POWR RATINGS... FREE!
FEMY Stock Price Chart Interactive Chart >
FEMY Price/Volume Stats
| Current price | $2.76 | 52-week high | $10.79 |
| Prev. close | $2.57 | 52-week low | $1.26 |
| Day low | $2.30 | Volume | 665,400 |
| Day high | $2.77 | Avg. volume | 288,955 |
| 50-day MA | $1.63 | Dividend yield | N/A |
| 200-day MA | $3.69 | Market Cap | 32.61M |
FEMASYS INC (FEMY) Company Bio
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Latest FEMY News From Around the Web
Below are the latest news stories about Femasys Inc that investors may wish to consider to help them evaluate FEMY as an investment opportunity.
Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer-- Seasoned financial executive with 25 years of experience leading public and private biotech companies throughout various stages -- ATLANTA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of Dov Elefant to chief financial officer (CFO), to be effective February 28, |
AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery ProceduresAcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of sufentanil sublingual tablet (SST) for pain management. |
When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven?AcelRx Pharmaceuticals, Inc. ( NASDAQ:ACRX ) is possibly approaching a major achievement in its business, so we would... |
Femasys Inc. Announces the Appointment of Wendy Perrow, Transformational Biotech Entrepreneur, as New Board MemberIndustry leader Wendy Perrow brings decades of expertise in fundraising, global product launches and corporate strategy to the Femasys teamATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of a new board member, Wendy Perrow. Ms. Perrow brings decades of experi |
Zacks Investment Research Downgrades Femasys (NASDAQ:FEMY) to HoldZacks Investment Research downgraded shares of Femasys (NASDAQ:FEMY) from a buy rating to a hold rating in a report issued on Monday morning, Zacks.com reports. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The [] |
FEMY Price Returns
| 1-mo | N/A |
| 3-mo | 22.12% |
| 6-mo | -29.23% |
| 1-year | -66.18% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -29.23% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...